Caribou Biosciences Inc (CRBU)vsModerna Inc (MRNA)
CRBU
Caribou Biosciences Inc
$1.31
+4.80%
HEALTHCARE · Cap: $136.15M
MRNA
Moderna Inc
$154.04
-2.55%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 22102% more annual revenue ($2.23B vs $10.04M). CRBU leads profitability with a 0.0% profit margin vs -141.4%. CRBU earns a higher WallStSmart Score of 23/100 (F).
CRBU
Avoid23
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+31.5%
Fair Value
$2.32
Current Price
$1.31
$1.01 discount
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$154.04
$19.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 9.1x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CRBU
The strongest argument for CRBU centers on Price/Book, Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : CRBU
The primary concerns for CRBU are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
CRBU profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
CRBU carries more volatility with a beta of 2.28 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
CRBU generates stronger free cash flow (-23M), providing more financial flexibility.
Bottom Line
CRBU scores higher overall (23/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Caribou Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Caribou Biosciences Inc. is a pioneering biotechnology firm specializing in genome editing through its proprietary CRISPR technology, aimed at developing transformative therapies for genetic disorders and oncology. With a robust and diversified pipeline addressing significant unmet medical needs, the company is well-positioned to lead advancements in precision medicine. Caribou's strategic collaborations and unwavering commitment to research excellence underpin its mission to revolutionize treatment paradigms and improve patient outcomes, establishing its foothold as a key player in the biopharmaceutical sector.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?